This article is more than 5 years old. Information may no longer be current.

FDA approves Avaclyr for herpetic keratitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved a new drug application for Avaclyr, Fera Pharmaceuticals’ herpetic keratitis treatment, according to a press release.

Avaclyr (acyclovir ophthalmic ointment 3%), a herpes simplex virus nucleoside analog DNA polymerase inhibitor, is indicated to treat dendritic ulcers in patients with HSV-1 and HSV-2, the release said.

In addition, Avaclyr was granted orphan drug exclusivity.

“Avaclyr approval is a major milestone for the company,” Frank DellaFera, Fera’s founder and president, said in the release. “Working closely with the eye care community we were able to identify a need for additional options to treat herpetic keratitis. Acyclovir is the gold standard treatment in herpes virus infections, so it made sense to provide this therapy in an ophthalmic dosage form.”